NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Dr. Strange Liau
Or
How I stopped worrying and learned to love the quietness.

Postulate:

Then you damn well better expect to answer to them when you haven't give them an update they deserve in over a year.

It's ridiculous that people here try to argue that management doesn't 'owe retail' anything. They sure as hell do.

Let's dissect that postulate for moment, remembering that the essential part about a quiet period is ... you're right. Keeping quiet.

But is that the case, or have retailers in other ways actually been quite well informed during the last 14 months?

During the last 14 months, following the data lock of October 5th. 2020, NWBO went into a quietness period (see Quiet Period), where seemingly no kind of information revolving around the companys activities, has been published.

This has been continuously used by naysayers of NWBO’s 14 year long trial of DCVax-L, as the primary focus point, to induce fear and doubt into shareholders. Sadly, with success.

But while this has been continuously and successfully brought forward, has that postulate any kind of validity to it? While the company has seemingly not been giving shareholders any kind of material information – which is also illegal – they have nevertheless been informing shareholders “between the lines” in other ways.

October 5th. 2020
Data lock occurs.

March 16th. 2021
Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

April 1st. 2021
Kristyn Power gets hired by NWBO as a Program Director in Toronto. She left her manager job at Deloitte. Her father being a long time GBM survivor due to the DCVax-L treatment.

May 1st. 2021
Tamara Kondic gets attached from Donahoe Consultants as an uplisting consultant. She is an expert in uplisting companies to NASDAQ, where the other Donahoe consultant being attached – Bruce Poignant – is an expert on uplisting to NYSE.

May 7th. 2021
Requesting MHRA certification of the Sawston facility to produce Good Manufacturing Practice (GMP) clinical grade medical products for patients.

June 16th. 2021
Patent granted by the Russian Federation:
RU0002749610 - Methods Related To Activated Dendritic Cells Compositions and To Immunotherapeutic Treatment of Individuals With Advanced Cancer

August 3rd. 2021
Patent granted by Canada: CA2490245 - Tangential Flow Filtration Devices And Methods For Leukocyte Enrichment

September 17th 2021
Linda M. Liau, MD, PhD, MBA, Primary Investigator of the #DCVax-L #GBM P3 clinical trial (US) was inducted to the Asian Hall of Fame 2021

September 30th. 2021
Patent granted by Israel: IL258071 - Methods Relating To Activated Dendritic Cell Compositions And Immunotherapeutic Treatments For Subjects With Advanced Cancers

October 10th. 2021
AdventBio hiring biobank manager, Facilities Coordinator, GMP production scientist, Process development Scientist, Quality Assurance Officer, Senior Production Scientist

October 28th. 2021

Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

November 15th. 2021
A Flaskworks patent application status with "Notice of Allowance": US17/074,893 - Systems And Methods For Cell Culturing

November 16th Q10 SEC filing.
Our operating costs also include the costs of preparations for new or expanded clinical trial programs, such as our planned Phase II clinical trials. The preparation costs include payments to regulatory consultants... Additional substantial costs relate to the maintenance and substantial expansion of manufacturing capacity, in both the U.S. and Europe.


November 19th. 2021
Patent granted by Japan : JP2018537949 - Activated Dendritic Cell composition for subjects with advanced cancer and methods for immunotherapeutic treatment

November 29th. 2021
Announces $15 mill. Financing to help accelerate activities related to brain cancer program


January 22nd 2022
Patent Forecasted Issue date. US application 13/492,693 - Compositions And Methods For Inducing The Activation Of Immature Monocytic Dendritic Cells

Quite a few other things has happened during that period, not least what has been discussed on the board, with regards to new definition of GBM that favours NWBO.

To state, that retailers haven't received any information during - nudge nudge - THE QUIET PERIOD, is substanceless at best.

QUIET PERIOD:

What is a quiet period?

“Quiet periods are mandated in conjunction with initial public offerings (IPOs), earnings seasons and other events that have significance for investors. The purpose of the quiet period is to ensure that no one with inside information can selectively disclose it to give particular investors an unfair advantage. Buying and selling securities based on non-public information, known as insider trading, is illegal.”


NWBO stated in PR May 12th regarding quiet period:

“The Company continues to be in a quiet period while this process is under way. The Company appreciates shareholders' patience, and their understanding that the Company cannot make partial disclosures during this process and cannot comment on the Phase III trial schedule or its data until the announcement of the results. We remain committed to completing the full plan outlined on October 5, 2020.”

And Linda Powers, followed up during ASM May 18th. 2021

“I’d like to be able to go into the details that we know everybody is craving, and understandably so, but we are in a quiet period now, while the data are being reviewed and analyzed. We’ve explained the process that we’re going through, it’s six stages of various analyses and reviews by various parties.”

Knowing NWBO’s history during the last 14 years of trial, one is enlightened about the forces in play, that through articles and use of SoMe, tried to sow doubt about the validity of science and not least about the integrity of the management, and there followed several cases of trying to instigate lawsuit of questionable grounds. Lawsuits that we know as “ambulance chasing event”, where second rate lawfirms try to earn money by harassing companies into settlements and the forces backing this scheme, enjoy the benefit of driving the sentiment down and thus the share price.